AI assistant
NOXOPHARM LIMITED — Capital/Financing Update 2018
May 20, 2018
65437_rns_2018-05-20_8fb1ced4-1dcd-403d-831c-10c43000f1e8.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [105 x 52] intentionally omitted <==
ASX RELEASE
21 May 2018
Securities to be released from Voluntary Escrow
Noxopharm Limited (“ NOX ” or the “ Company ”) (ASX: NOX) advises that in accordance with ASX Listing Rule 3.10A, the following securities are due for release from voluntary escrow:
| Security Description | Number | Date of Release |
|---|---|---|
| Ordinary Shares | 5,970,714 | 14 June 2018 |
The aforesaid Ordinary Shares being released from escrow (representing approximately 4.90% of the Company’s shares) are currently quoted on the ASX and as such quotation of these shares will not be required.
David Franks P: +61 2 9299 9690 E: [email protected]
ABOUT NOXOPHARM LIMITED
Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy and chemotherapy. NOX66 is the first pipeline product.